The upper and lower respiratory tract microbiome in severe aspiration pneumonia.
Clinical finding
Microbiome
Respiratory medicine
Journal
iScience
ISSN: 2589-0042
Titre abrégé: iScience
Pays: United States
ID NLM: 101724038
Informations de publication
Date de publication:
16 Jun 2023
16 Jun 2023
Historique:
received:
19
09
2022
revised:
24
01
2023
accepted:
03
05
2023
medline:
30
5
2023
pubmed:
30
5
2023
entrez:
30
5
2023
Statut:
epublish
Résumé
Uncertainty persists whether anaerobic bacteria represent important pathogens in aspiration pneumonia. In a nested case-control study of mechanically ventilated patients classified as macro-aspiration pneumonia (MAsP, n = 56), non-macro-aspiration pneumonia (NonMAsP, n = 91), and uninfected controls (n = 11), we profiled upper (URT) and lower respiratory tract (LRT) microbiota with bacterial 16S rRNA gene sequencing, measured plasma host-response biomarkers, analyzed bacterial communities by diversity and oxygen requirements, and performed unsupervised clustering with Dirichlet Multinomial Models (DMM). MAsP and NonMAsP patients had indistinguishable microbiota profiles by alpha diversity and oxygen requirements with similar host-response profiles and 60-day survival. Unsupervised DMM clusters revealed distinct bacterial clusters in the URT and LRT, with low-diversity clusters enriched for facultative anaerobes and typical pathogens, associated with higher plasma levels of SPD and sCD14 and worse 60-day survival. The predictive inter-patient variability in these bacterial profiles highlights the importance of microbiome study in patient sub-phenotyping and precision medicine approaches for severe pneumonia.
Identifiants
pubmed: 37250794
doi: 10.1016/j.isci.2023.106832
pii: S2589-0042(23)00909-4
pmc: PMC10212968
doi:
Types de publication
Journal Article
Langues
eng
Pagination
106832Subventions
Organisme : BLRD VA
ID : IK2 BX004886
Pays : United States
Informations de copyright
© 2023 The Author(s).
Déclaration de conflit d'intérêts
G.D.K. has received research funding from Karius, Inc and Pfizer, Inc. A.M. has received research funding from Pfizer, Inc. B.J.M. has received research funding from Bayer Pharmaceuticals, Inc., consulting fees from Boehringer Ingelheim, BioAegis and Synairgen, and payments from expert testimony from VeraMedica, LLC. The other authors have no conflicts of interest to disclose.
Références
Anaerobe. 2021 Jun;69:102325
pubmed: 33540111
PLoS One. 2021 Oct 1;16(10):e0257521
pubmed: 34597327
Thorax. 2021 Dec;76(12):1231-1235
pubmed: 33888575
Crit Care Explor. 2021 Dec 09;3(12):e0591
pubmed: 34909698
BMC Pulm Med. 2016 May 11;16(1):79
pubmed: 27169775
J UOEH. 2019;41(2):185-192
pubmed: 31292363
Am J Respir Crit Care Med. 2019 Oct 1;200(7):e45-e67
pubmed: 31573350
Crit Care Med. 2005 Jun;33(6):1191-8
pubmed: 15942330
Crit Care Med. 2012 May;40(5):1470-7
pubmed: 22430234
Nat Biotechnol. 2019 Jul;37(7):783-792
pubmed: 31235920
J Hosp Med. 2015 Feb;10(2):90-6
pubmed: 25363892
Intern Emerg Med. 2014 Dec;9(8):879-85
pubmed: 25164409
Crit Care. 2013 Oct 24;17(5):R253
pubmed: 24156650
Sci Rep. 2014 Mar 11;4:4345
pubmed: 24614401
Am J Respir Crit Care Med. 2020 Dec 15;202(12):1666-1677
pubmed: 32717152
Am J Respir Crit Care Med. 2020 Mar 1;201(5):555-563
pubmed: 31973575
Proc Natl Acad Sci U S A. 2018 Dec 26;115(52):E12353-E12362
pubmed: 30482864
Clin Infect Dis. 2016 Sep 1;63(5):e61-e111
pubmed: 27418577
Arch Intern Med. 1975 May;135(5):711-4
pubmed: 28705
Am J Respir Crit Care Med. 2013 May 15;187(10):1067-75
pubmed: 23491408
PLoS One. 2012;7(2):e30126
pubmed: 22319561
Crit Care Explor. 2022 May 18;4(5):e0699
pubmed: 35620769
Am J Respir Crit Care Med. 2021 May 1;203(9):1099-1111
pubmed: 33166473
N Engl J Med. 2019 Feb 14;380(7):651-663
pubmed: 30763196
Ann Otol Rhinol Laryngol. 2018 Jan;127(1):21-32
pubmed: 29188729
Genome Res. 2016 Dec;26(12):1721-1729
pubmed: 27852649
Am J Respir Crit Care Med. 2021 Oct 15;204(8):921-932
pubmed: 34409924
mBio. 2017 Feb 14;8(1):
pubmed: 28196961
Open Forum Infect Dis. 2020 Sep 15;7(9):ofaa307
pubmed: 32968689
Crit Care Med. 2019 Dec;47(12):1724-1734
pubmed: 31634231
BMC Pulm Med. 2019 Dec 23;19(1):260
pubmed: 31870355
Am J Respir Crit Care Med. 2018 Aug 1;198(3):294-297
pubmed: 29522689
Front Microbiol. 2018 Jul 10;9:1413
pubmed: 30042738
Genome Med. 2021 Nov 17;13(1):182
pubmed: 34784976
Crit Care. 2010;14(2):209
pubmed: 20236452
Crit Care. 2022 Jul 6;26(1):203
pubmed: 35794610
Am J Respir Crit Care Med. 2021 May 1;203(9):1049-1051
pubmed: 33596387
Nat Methods. 2015 Feb;12(2):115-21
pubmed: 25633503
Eur Respir J. 2023 Feb 9;61(2):
pubmed: 36229047
Respir Res. 2019 Nov 27;20(1):265
pubmed: 31775777
J Crit Care. 2017 Apr;38:84-91
pubmed: 27866110
mSystems. 2018 Mar 13;3(2):
pubmed: 29556537
Chest. 2021 Jan;159(1):58-72
pubmed: 32687909